0001493152-24-011034.txt : 20240322 0001493152-24-011034.hdr.sgml : 20240322 20240322180015 ACCESSION NUMBER: 0001493152-24-011034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220315 FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Callahan Jennifer L. CENTRAL INDEX KEY: 0001883523 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40874 FILM NUMBER: 24776468 MAIL ADDRESS: STREET 1: C/O CINGULATE INC. STREET 2: 1901 W. 47TH PLACE CITY: KANSAS CITY STATE: KS ZIP: 66205 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cingulate Inc. CENTRAL INDEX KEY: 0001862150 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 863825535 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1901 W. 47TH PLACE CITY: KANSAS CITY STATE: KS ZIP: 66205 BUSINESS PHONE: (913) 942-2300 MAIL ADDRESS: STREET 1: 1901 W. 47TH PLACE CITY: KANSAS CITY STATE: KS ZIP: 66205 4 1 ownership.xml X0508 4 2022-03-15 0 0001862150 Cingulate Inc. CING 0001883523 Callahan Jennifer L. 1901 W. 47TH PLACE KANSAS CITY KS 66205 0 1 0 0 SVP and CFO 0 Common Stock 2022-03-15 4 P 0 55 27.10 A 2333 D Warrant to Purchase Common Stock 120 2022-03-15 4 P 0 1500 0.3007 A 2021-12-10 2026-12-10 Common Stock 75 21030 D The number of shares and price reflect the 1-for-20 reverse stock split of the Issuer's issued and outstanding shares of common stock, which became effective on November 30, 2023. Total number of securities includes purchases reflected on Forms 4 filed subsequent to the purchases this Form 4 covers. The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.2999 to $0.3094 per warrant, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth herein. Jennifer L. Callahan 2024-03-22